Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/30446
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Neeson P. | en |
dc.contributor.author | Ritchie D.S. | en |
dc.contributor.author | Quach H. | en |
dc.contributor.author | Fielding K. | en |
dc.date.accessioned | 2021-05-14T10:17:35Z | en |
dc.date.available | 2021-05-14T10:17:35Z | en |
dc.date.copyright | 2010 | en |
dc.date.created | 20100527 | en |
dc.date.issued | 2010-05-27 | - |
dc.date.issued | 2010-05-27 | en |
dc.identifier.citation | Immunotherapy. 2 (2) (pp 243-255), 2010. Date of Publication: March 2010. | en |
dc.identifier.issn | 1750-743X | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/30446 | en |
dc.description.abstract | Multiple myeloma is an immunologically relevant disease, which subverts and suppresses immunity, but that may also be amenable to immunological control. Novel drug and cell-based therapies provide an opportunity for the design of antimyeloma immunotherapy. Reversing the immunosuppression associated myeloma remains a substantial challenge. The minimal residual disease setting achieved by autologous stem cell transplant or highly efficacious induction therapy may reverse this immunoparesis and provide a setting for induction of antimyeloma T-cell responses. Adoptive cytotoxic T-lymphocyte/NK therapy and comprehensive treatment with immunomodulatory drug therapy represent means by which antimyeloma immune responses may be promoted. In addition, apoptosis-inducing therapies may prime endogenous antigen presentation via immunogenic cell death, which again may be enhanced by the addition of immunomodulatory drug therapy. © 2010 Future Medicine Ltd. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Future Medicine Ltd. (E-mail: info@futuremedicine.com) | en |
dc.relation.ispartof | Immunotherapy | en |
dc.title | Drug-mediated and cellular immunotherapy in multiple myeloma. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2217/imt.10.9 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 20635931 [http://www.ncbi.nlm.nih.gov/pubmed/?term=20635931] | en |
dc.identifier.source | 358444637 | en |
dc.identifier.institution | (Ritchie, Quach, Fielding, Neeson) Haematology and Immunology Translational Research Laboratory, Cancer Immunology Research Program, Locked Bag 1, ABeckett St, East Melbourne, VIC 8000, Australia (Ritchie) Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, ABeckett St, East Melbourne, VIC 8000, Australia (Ritchie) University of Melbourne, Parkville, VIC, Australia (Quach) Monash Medical Centre, Clayton, VIC, Australia | en |
dc.description.address | D. S. Ritchie, Haematology and Immunology Translational Research Laboratory, Cancer Immunology Research Program, Locked Bag 1, ABeckett St, East Melbourne, VIC 8000, Australia. E-mail: david.ritchie@petermac.org | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2015 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Adoptive immunotherapy Immunogenic cell death Immunomodulatory drug Myeloma Vaccination | en |
dc.identifier.authoremail | Ritchie D.S.; david.ritchie@petermac.org | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.